Summary A systematic review of the literature was undertaken to assess what published evidence is currently available to support the increasing use of autologous stem cell transplantation (ASCT), and to evaluate the published data with regard to the comparative cost of highdose and conventional therapy. The review aimed to identify all published, randomized controlled trials (RCTs) comparing high-dose therapy (HDT) with ASCT versus conventional chemotherapy (CC) in acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and breast, lung, testicular and ovarian cancer. The review also aimed to identify all studies that had compared the cost of the two treatment strategies. Reports were identi¢ed by systematic searches of Cancerlit, Embase and Medline, and handsearching of several conference proceedings. Where possible, pooled odds ratios (ORs) were calculated according to the ¢xed-e¡ect model. A total of 18 randomized trials were identi¢ed in acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and breast, lung and testicular cancer. Trials were generally small and no disease site had su¤cient information to determine reliably whether high-dose therapy with autologous transplant is more e¡ective than CC. Five studies were identi¢ed that compared the cost of the two treatments. These found the cost of HDT to be between one and four times higher than that of CC. Further randomized trials are required. Where appropriate, these should include economic assessment and assessments of long-term toxicity.
Introduction
The use of high-dose therapy (HDT) employing myeloablative treatment and haematopoietic rescue is increasing in both haematological and non-haematological malignancies. Data from the International Bone Marrow Transplantation Registry and the Autologous Blood and Bone Marrow Transplant Registry estimated that around 500 autologous transplants were performed worldwide in1970 (Horowitz & Rowlings 1997) with this ¢gure rising to over 17,000 in1995. The factors behind this increase have been widely discussed, and relate to the unsatisfactory results of conventional treatment, reports of dose^response relationships for some malignancies (at least in vitro), encouraging reports from single institutions and registry-based series, together with reductions in morbidity owing to the use of growth factor-mobilized haemopoietic progenitors and improvements in supportive care. These have encouraged the use of progenitor cell transplants in the treatment of a number of diseases where the risks of therapy were previously thought to outweigh the potential bene¢ts.
Despite several thousand publications reporting the results of transplant series, there is still great uncertainty 61 as to the true e¡ectiveness of HDT and progenitor cell transplants. The treatment is often viewed as expensive and toxic. A systematic reviewof the randomized literature was therefore undertaken (Johnson et al.1998 ) to evaluate the e¤cacy of high-dose therapy with autologous transplantation (HDT(autol)) compared with conventional chemotherapy (CC). This review as a whole investigated both autologous and allogeneic transplantation. The latter also considered evidence from non-randomized controlled clinical trials because insu¤cient randomized evidence was available. This paper, however, is restricted to the evidence relating to autologous transplantation where only randomized controlled trials were considered.) Results for acute lymphoblastic leukaemia, malignant lymphoma, multiple myeloma, breast, lung and testicular cancer are presented here. No randomized trials were identi¢ed for chronic myeloid and chronic lymphocytic leukaemia or for ovarian cancer. The data on autologous transplantation in acute myeloid leukaemia are not reported because an individual patient data meta-analysis has recently been completed by the International Acute Myeloid Leukaemia Collaborative Group (M. Clarke, personal communication), which will give a more reliable assessment of e¡ec-tiveness. The disease sites investigated represent the areas in which most transplant activity has been focused and where, owing to the incidence of the illnesses, the clinical and economic impact is likely to be greatest. The literature on the comparative cost of HDT and progenitor cell transplantationvs. conventional therapyhas also been systematically reviewed and is included inthis report.
Methods
The methods for trial identi¢cation and analysis of results were speci¢ed prospectively. Published studies were identi¢ed using electronic literature searches of Cancerlit, Embase, Medline and the NHS Economic Evaluation Database (completed on January 1, 1997). A second search for randomized controlled trials (RCTs) using a modi¢ed version of the Cochrane Collaboration optimal search strategy was completed on June 1, 1997. This was supplemented by hand searching conference proceedings of the European Bone Marrow Transplantation Group (1992^97), International Society for Experimental Hematology (1992^96) and European Haematology Association (1994^96). In addition, the UK Coordinating Committee on Cancer Research Cancer Trials Register and the National Cancer Institute PDQ database were searched for reports of eligible ongoing and unpublished trials, although no additional information was sought from these trials.
Only randomized trials were included in the analysis. Tables of non-randomized studies and of ongoing randomized trials are presented elsewhere (Johnson et al. 1998) . Randomization could have been at any stage of the illness, for example as ¢rst-line therapy, consolidation of response or second-line therapy. Studies should also have reported on overall survival or progression-free survival, where progression-free survival was de¢ned as patients alive and progression-free at the time of analysis. There were no language restrictions and no judgement was made as to whether the high-dose therapy was truly myeloablative. For economic comparisons, studies were included if the report made an economic evaluation of HDT compared with CC. Decisions on the inclusion of potentially eligible papers, together with data extraction, were carried out independently by two reviewers. Any discrepancies were resolved by discussion and by seeking a third opinion where necessary.
Odds ratios (ORs) were combined using the Peto method according to the ¢xed-e¡ects model. Where ORs were not presented in the paper at the time-points of interest, the statistic was calculated from observed and expected number of events taken from the paper or calculated from survival curves. In-house software was used to perform statistical analysis and to produce plots. The w 2 -test for heterogeneity (Early Breast Cancer Trialists' Collaborative Group 1990) was used to test for gross statistical heterogeneity between individual trials and the w 2 -test for interaction to test for gross statistical heterogeneity between groups of trials. Unless otherwise stated, all P-values are on1degree of freedom.
Results
Across all the disease sites investigated, 18 RCTs (Humblet et al. 1987; Fiere et al. 1990; Fiere et al. 1994; Bernasconi et al. 1992; Chevreau et al. 1993; Linch et al. 1993; Attal et al. 1994; Sebban et al. 1994; Bezwoda, Seymour & Dansey 1995; Fermand et al. 1995; Ljungman et al. 1995; Philip et al. 1995; Verdonck et al. 1995; Gisselbrecht et al. 1996; Martelli et al. 1996; Peters et al. 1996; Gianni et al. 1997; Haioun et al. 1997; Santini et al. 1999) of HDT(autol) versus conventional therapy were identi¢ed, the majority of which used bone marrow as the source of progenitor cells. Three trials were in adult acute lymphoblastic leukaemia, seven in non-Hodgkin's lymphoma, one in Hodgkin's disease, two in multiple myeloma, three in breast cancer, one each in lung cancer and germ-cell tumours, and none in ovarian cancer, chronic myeloid leukaemia or chronic lymphocytic leukaemia. The results of individual trials are summarized in Table1, and Table 2 of the available information and overall results by disease site.
Acute lymphoblastic leukaemia
Three RCTs (Fiere et al. 1990; Sebban et al. 1994; Bernasconi et al. 1992) , including 213 patients in total, were identi¢ed. All randomized adult patients in ¢rst complete remission following induction therapy to receive HDT or conventional consolidation treatment. None of the trials reported a di¡erence in survival or progression-free survival. Owing to incomplete data reporting, no quantitative synthesis was possible.
Non-Hodgkin's lymphoma
Seven RCTs (Philip et al. 1995; Verdonck et al. 1995; Gisselbrecht et al. 1996; Martelli et al. 1996; Haioun et al. 1997; Gianni et al. 1997; Santini et al. 1999) were identi¢ed, including 1192 patients randomized between 1987 and 1995. All investigated HDT in the treatment of intermediate-and high-grade lymphoma, but in patients with differing characteristics or at di¡erent stages in the history of the lymphoma.
First-line induction therapy
Three trials (Gisselbrecht et al. 1996; Gianni et al. 1997; Santini et al. 1999) were identi¢ed that investigated the use of HDT as a component of ¢rst-line therapy, one of which (Gianni et al. 1997 ) randomized patients to immediate versus delayed HDT on relapse. The pooled OR for survival at 3/4 years for two trials showed no evidence of a di¡erence between the two treatments (OR 0.77; 95% CI 0.57^1.47; Figure 1 ). Two trials reported on progression-free survival: one (Gianni et al. 1997 ) reported a signi¢cant bene¢t for HDT; the other (Gisselbrecht et al. 1996) reported a signi¢cant bene¢t for CC. Insu¤cient data were included in the reports to allow summation of this data.
Consolidation of first complete remission
One comparatively large trial (Haioun et al. 1997) was identi¢ed. This randomized 541 patients in ¢rst complete remission who were de¢ned as poor risk according to the Coi¤er criteria (Coi¡er 1991) . No evidence of a di¡erence in overall survival or progression-free survival was reported.
Consolidation of first remission in slow responders
Two RCTs Martelli et al. 1996) were identi¢ed that included a total of 118 patients who responded slowly to ¢rst-line induction therapy. Pooled ORs for overall survival and progression-free survival at 4 years showed no evidence of a di¡erence between treatments, with an OR of 1.73 (95% CI 0.08^3.75) for survival and an OR for progression-free survival of 0.96 (95% CI 0.47^1.99) (Figures1and 2, respectively).
Consolidation of first remission ± all trials
Pooling the results of 4 years'survival for all trials of consolidation of ¢rst remission gave an OR of 1.02 (95% CI 0.74^1.42) (Figure 1 ). For progression-free survival the overall OR was 0.86 (95% CI 0.63^1.18) (Figure 2 ).
Consolidation of second or third remission
One RCT (Philip et al. 1995) was identi¢ed that randomized109 patients. This reported a signi¢cant overall survival and progression-free survival advantage in favour of HDT (P 0.038 and P 0.001, respectively; Figures 1 and  2 ). However, a greater number of patients (40%) on the HDT arm received radiotherapy compared with the CC arm (22%).
Hodgkin's disease
A single trial (Linch et al. 1993 ) was identi¢ed that randomized 40 patients resistant to, or relapsed following, ¢rst-line chemotherapy. The trial reported an advantage in 
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Multiple myeloma
The two trials identi¢ed (Attal et al. 1994; Fermand et al. 1995) reported on a total of 357 patients randomized between 1990 and 1994. The pooled OR of 0.68 for 2 years' survival showed no clear evidence of a di¡erence between treatments (95% CI 0.42^1.10; P 0.12; Figure  3 ), whilst the pooled OR of 0.39 for progression-free survival at 2 years was signi¢cantly in favour of HDT (95% CI 0.25^0.59; P < 0.001; Figure 4 ).
Solid tumours
Breast cancer. Three trials (Bezwoda et al. 1995; Ljungman et al. 1995; Peters et al. 1996) were identi¢ed that reported on 197 patients with advanced breast cancer randomized between 1988 and 1995. Two trials (Ljungman et al. 1995; Peters et al. 1996) randomized patients responding to initial chemotherapy, whereas in the third (Ljungman et al. 1995) no chemotherapy was administered prior to randomization. The largest trial (Peters et al. 1996) , which randomized patients to immediate versus HDT(autol) on relapse, reported a signi¢cant survival bene¢t in favour of CC, but a signi¢cant progression-free survival bene¢t in favour of HDT; no details were given as to the number of patients in the conventional arm who relapsed and received a late transplant. A second trial (Ljungman et al. 1995) reported no survival statistics and no progression-free survival data. However, a calculated OR for survival at 2 years was conventionally signi¢cant in favour of HDT with an OR of 0.10 (99% CI 0.03^0.35; P < 0.001). The use of maintenance tamoxifen could potentially confound these results as a greater number of HDT patients responded to treatment and were therefore o¡ered tamoxifen. The third trial (Peters et al. 1996) , which randomized only nine patients, stopped early owing to poor accrual, and reported no survival or progression-free survival data. Insu¤cient information was included in the reports to allow data summation. Testicular cancer. The single RCT (Chevreau et al. 1993) identi¢ed randomized 114 patients with poor prognosis metastatic germ cell tumours between1988 and1991. The trial found no evidence of an overall survival or progression-free survival di¡erence between the two treatments, although the planned dose of cisplatin, the most active agent administered, was identical in both arms of the trial.
Small cell lung cancer. One trial (Humblet et al. 1987 ) was identi¢ed that randomized 45 patients in complete remission or partial remission after induction chemotherapy. The trial found no evidence of a di¡erence in overall survival but reported a progression-free survival advantage in favour of HDT (P 0.002). 
Economic studies
Only one study (Uyl de Groot et al. 1995 ) that based its results on the ¢ndings of an RCT was identi¢ed (Table 3) . This study evaluated the cost of treating 42 of 69 patients with non-Hodgkin's lymphoma who were randomized in a trial of postremission therapy for slow responders (Verdonck et al. 1995) (Table1). Twenty-one patients were treated with HDT and 21 patients with CC. No mention was made as to how the 42 patients were selected from the total number randomized. This study concluded that the average cost over the ¢rst 2 years of therapy (with discounting at 5%) was US $49,983 for HDT and US $15,285 for CC. This di¡erence in cost was mainly a result of the additional costs incurred during the treatment period. Four non-randomized comparisons were also identi¢ed Henon et al. 1994; Zaidi, Clarke & Hutchinson 1996) (Table 3) , evaluating the cost in multiple myeloma, non-Hodgkin's lymphoma, relapsed Hodgkin's disease and breast cancer. These studies found the cost of HDT to be between one and four times higher than the cost of CC.
Discussion
HDT with autologous stem cell transplantation has been under investigation for over 30 years and, for some diseases, has become established as a routine component of treatment. Despite the publication of hundreds of case series and cohort studies involving thousands of patients, few randomized trials have compared this approach with standard therapy. Consequently, the use of such treatment in many malignancies is guided by little reliable evidence and, in most cases, it is unclear whether it o¡ers any survival advantage over conventional therapy. This systematic review was therefore undertaken to appraise the available published evidence concerning the e¤cacy of HDT(autol), in a number of key cancers. Although the review only includes studies reported prior to January 1997, randomized trials published since that time have supported the results of preliminary analysis and do not a¡ect the overall conclusions of this review (Santini, Salvagno & Leoni1998; Rodenhuis et al. 1998) .
As this systematic review is based only on published trial reports, it could be subject to a number of potential biases (Stewart & Parmar 1993) , including those relating to unavailable trials, incomplete data and restrictions on the type of analyses that could be performed. Importantly, there are a number of closed, but as yet unpublished, trials that were not available for inclusion in the review such that publication bias (Dickersin, Min & Meinert 1992 ) (where the results of positive trials are more likely to be published than those with`negative' or inconclusive results) could be a problem.
For no disease site was there su¤cient randomized evidence to determine reliably whether or not HDT(autol) gives superior overall or progression-free survival compared with CC. For several disease sites only single RCTs were identi¢ed. These were all small, randomizing between 45 and 109 patients, and were therefore unable to detect reliably moderate di¡erences in survival and progression-free survival. Even for those sites where several trials were identi¢ed, the total number of patients randomized across all trials was still modest. For example, in the consolidation of slow responders in non-Hodgkin's lymphoma, two trials were identi¢ed that together included only 118 patients. Owing to the small number of published RCTs and to insu¤cient reporting of data in trial publications, quantitative synthesis was only possible in a few instances and the results of these analyses must be viewed with caution.
As would be expected from their small size, the results for overall survival in individual trials are mostly inconclusive, although three out of 14 trials that presented such data reported marginally signi¢cant results (at conventional levels) in favour of HDT. Of the 13 trials that reported on progression-free survival, eight found signi¢-cant bene¢t in favour of HDT. Several of the trials were designed to compare immediate transplantation versus later transplantation and it is important to consider that in other trials patients may also have crossed-over from conventional to HDT. This could reduce the likelihood of overall survival di¡erences despite improvements in progression-free survival, and as most reports do not specify what proportion of patients crossed-over in this way, it is di¤cult to determine any e¡ect of this strategy. It must, however, be noted that patients crossing-over from conventional treatment to HDT and progenitor cell transplantation re£ects current clinical practice. Evaluation of issues such as quality of life, long-term toxicity and health economics will be necessary to determine whether transplanting early or on relapse is the most appropriate strategy, if no survival di¡erence is seen.
Data synthesis was possible only in two disease sites. For non-Hodgkin's lymphoma the overall ORs for 4-year survival are inconclusive with the results for ¢rst-line therapy favouring HDT and those for the consolidation of ¢rst remission favouring CC. On the end-point of progression-free survival, a combined OR could only be calculated for ¢rst remission; again this was inconclusive but favoured HDT. In multiple myeloma the combined OR for 2-year survival favours HDT, but is inconclusive, and for 2-year progression-free survival a conventionally signi¢-cant result in favour of HDT is observed. As discussed in the methods section, there are considerable limitations on the type of analysis possible with a systematic review of the literature such as this. In particular, not all trials present su¤cient information to be included in the analyses, and the time-points for which these analyses are carried out are constrained by the data that is presented in trial reports. Consequently, all the quantitative analyses presented must be interpreted with caution. As a whole, the review has found no conclusive evidence that HDT(autol) is superior to conventional treatment in terms of survival or progression-free survival. Conversely, it has not demonstrated that it is inferior and, given the overall pattern of results, it appears to be a therapy worthy of further exploration.
Only one small economic study that used the results of an RCT as an e¤cacy measure was identi¢ed and it is not possible to draw conclusions as to the relative cost of HDT(autol) with CC in any disease site. It is, however, apparent from non-randomized studies that the relative costs vary widely between studies and disease sites. It is probable that this relates as much to the methodology and assumptions used in calculating the costs as to real di¡er-ences, but until standard analyses are available for comparison, health economic assessment may be necessary for all the various disease sites.
There is continuing pressure from patients and physicians to broaden the application of HDT and progenitor cell transplants. At present, despite thousands of patients having been treated, there is very little reliable evidence of its e¤cacy. In some malignancies, for instance relapsed Hodgkin's disease or aggressive non-Hodgkin's lymphoma in second remission, the use of HDT has become so well established (on the basis of results from non-randomized studies, or very small randomized trials), that there is now no realistic prospect of conducting new trials against conventional therapy. However, for other cancers where the use of HDT/progenitor transplantation is relatively new, there is an urgent need for high-quality research to ensure that any future introduction and use is guided by reliable evidence. There are at present several ongoing randomized trials in the disease sites investigated. It is critical to ensure that a su¤ciently high number of patients are randomized in these studies, and any new studies, to give su¤cient power to detect moderate di¡erences in outcome. Where appropriate, these trials should also incorporate extended follow-up in order to evaluate possible long-term toxic e¡ects and economic evaluations, both of which are currently lacking. More complete reporting of trial results (ideally using the CONSORT (Consolidated Standards of Reporting Trials) guidelines; Begg et al. 1996) is also necessary so that clinical judgements can be made on all the available results of a trial, not just the highlights. It is worrying that patients are routinely treated with a therapy whose e¤cacy and longterm side-e¡ects have yet to be reliably evaluated. The ideal practice should therefore be to consider entering all patients for whom autologous transplantation is a treatment option into a randomized controlled trial.
